3 Pharmaceuticals Maker, Life Sciences Services Company and Footwear Retailer Stocks With a Strong Future Roadmap: Lupin, Indegene and Metro Brands

Pharma, life science and footwear retail stocks give investors a way to track businesses that sit close to everyday demand in India. Lupin, Indegene and Metro Brands cover a pharmaceuticals maker, a life sciences services company and a footwear retailer.

This list covers three pharma, life science and footwear retail stocks with complete current figures: Lupin, Indegene and Metro Brands. Every figure comes from the latest reported financials and the 12 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Pharma, Life Science and Footwear Retail Stocks?

Pharma, life science and footwear retail stocks are listed companies that make and sell medicines in India and global markets, provide commercial and data services to drug and medical device makers, and run large footwear stores for branded labels. Their earnings depend on medicine demand, client spending and consumer footfall.

Pharma, Life Science and Footwear Retail Stocks at a Glance

On valuation, Lupin and Indegene trade at a P/E below the industry P/E, while Metro Brands trades above it, which reflects the growth the market already expects. Readers comparing pharma, life science and footwear retail stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Pharma, Life Science and Footwear Retail Stocks Have a Strong Roadmap in India?

Pharma, life science and footwear retail stocks have a strong roadmap in India because rising demand for quality medicines, growing outsourcing by drug makers and strong appetite for branded footwear keep widening the market for these companies.

• Pharmaceuticals. Patients need quality medicines.
• Life sciences services. Drug makers outsource commercial work.
• Footwear retail. Shoppers upgrade to branded footwear.

Why Lupin Features Among These Pharma, Life Science and Footwear Retail Stocks

Among the pharma, life science and footwear retail stocks on this list, Lupin is a Mumbai-headquartered global pharmaceutical company with a presence in branded generics in India, complex generics and specialty products in the United States, and active ingredients, with strength in respiratory, cardiovascular, anti-diabetic and anti-infective therapies.

The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P/E of 16.1, below the industry P/E of 36.0.

Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%. In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore.

Roadmap: The company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.

What to watch: Track key launches in the United States, especially in inhalation and complex injectables, and the growth of the India branded business.

Why Indegene Features Among These Pharma, Life Science and Footwear Retail Stocks

Among the generic medicines, drug commercialisation and shoe store shares on this list, Indegene is a Bengaluru-based healthcare technology and services company that helps biopharma and medical technology firms with commercial, medical and regulatory work using data and technology.

Revenue rose from Rs 1,690 crore in FY22 to Rs 3,582 crore in FY26, a compound annual growth rate of 20.7%. Net profit grew from Rs 163 crore in FY22 to Rs 401 crore in FY26, which works out to a compound annual growth rate of 25.3%.

In the June 2026 quarter, revenue grew 39.5% year on year to Rs 1,092 crore. The company has a return on equity of 12.8%, a debt to equity ratio of 0.05 and a market capitalisation of Rs 14,454 crore. The stock trades at a P/E of 36.0, below the industry P/E of 59.2.

Roadmap: The company is widening its digital and artificial intelligence services for life sciences clients and adding new customers across drug and device makers. Multi-year contracts with global clients support recurring revenue.

What to watch: Monitor client additions, platform adoption and growth in artificial intelligence services.

Why Metro Brands Features Among These Pharma, Life Science and Footwear Retail Stocks

Among the three companies on this list, Metro Brands is a Mumbai-based footwear retailer operating the Metro, Mochi, Walkway and Crocs outlets, and also selling through online channels and select partner brands.

Revenue rose from Rs 1,402 crore in FY22 to Rs 2,968 crore in FY26, a compound annual growth rate of 20.6%. Net profit grew from Rs 213 crore in FY22 to Rs 416 crore in FY26, which works out to a compound annual growth rate of 18.2%.

The company has a return on equity of 19.8%, a debt to equity ratio of 0.76 and a market capitalisation of Rs 23,316 crore. The stock trades at a P/E of 55.4, above the industry P/E of 37.0.

Roadmap: The company is opening new stores across cities and adding premium and international brands to its range. An omni-channel presence helps it reach a wider set of shoppers.

What to watch: Track store openings, premium brand share and online sales.

Lupin vs Indegene vs Metro Brands on Key Financials

The table below sets the three pharma, life science and footwear retail stocks side by side on revenue, profit and margin, using reported figures.

Lupin posts the highest return on equity in this group at 23.8%. Lupin has the largest FY26 revenue at Rs 29,039 crore, and Indegene shows the fastest revenue growth with a 20.7% compound annual rate. A useful habit with pharma, life science and footwear retail stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Pharma, Life Science and Footwear Retail Stocks

Every theme carries risks that deserve a check before any decision. For these pharma, life science and footwear retail stocks, the main points are: Long-term generic medicines, drug commercialisation and shoe store shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Regulatory approvals. Plant inspections and approvals can affect supplies.
• Client concentration. A few large clients contribute a big share of revenue.
• Footfall and spending. Store sales follow consumer mood and seasons.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter pharma, life science and footwear retail stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Pharma, Life Science and Footwear Retail Stocks

Pharma, life science and footwear retail stocks work best when investors track growth, valuation and return on equity side by side. Lupin, Indegene and Metro Brands each have a clear plan to grow. Based on the 12 November 2026 close, Lupin trades at Rs 2,015, Indegene at Rs 666.05 and Metro Brands at Rs 836.

Download the Univest iOS App or Univest Android App to track pharma, life science and footwear retail stocks, set price alerts and get research-backed stock ideas.

What are pharma, life science and footwear retail stocks?

Ans. Pharma, life science and footwear retail stocks are listed companies that make and sell medicines in India and global markets, provide commercial and data services to drug and medical device makers, and run large footwear stores for branded labels. Their earnings depend on medicine demand, client spending and consumer footfall. This list looks at three of them, Lupin, Indegene and Metro Brands, using reported FY22 to FY26 financials and the 12 November 2026 closing prices.

Which pharma, life science and footwear retail stocks are covered in this list?

Ans. This list covers Lupin, Indegene and Metro Brands. Based on the 12 November 2026 close, Lupin traded at Rs 2,015, Indegene at Rs 666.05 and Metro Brands at Rs 836. Their return on equity ranges from 12.8% to 23.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 15.0% to 20.7%.

Why do pharma, life science and footwear retail stocks have a strong future roadmap in India?

Ans. Pharma, life science and footwear retail stocks have a strong roadmap in India because rising demand for quality medicines, growing outsourcing by drug makers and strong appetite for branded footwear keep widening the market for these companies. The main drivers are as follows. Pharmaceuticals. Patients need quality medicines. Life sciences services. Drug makers outsource commercial work. Footwear retail. Shoppers upgrade to branded footwear. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Lupin performed financially?

Ans. Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%. In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore. The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P/E of 16.1, below the industry P/E of 36.0. Looking ahead, the company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.

How has Indegene performed financially?

Ans. Revenue rose from Rs 1,690 crore in FY22 to Rs 3,582 crore in FY26, a compound annual growth rate of 20.7%. Net profit grew from Rs 163 crore in FY22 to Rs 401 crore in FY26, which works out to a compound annual growth rate of 25.3%. In the June 2026 quarter, revenue grew 39.5% year on year to Rs 1,092 crore. The company has a return on equity of 12.8%, a debt to equity ratio of 0.05 and a market capitalisation of Rs 14,454 crore. The stock trades at a P/E of 36.0, below the industry P/E of 59.2. Looking ahead, the company is widening its digital and artificial intelligence services for life sciences clients and adding new customers across drug and device makers. Multi-year contracts with global clients support recurring revenue.

How has Metro Brands performed financially?

Ans. Revenue rose from Rs 1,402 crore in FY22 to Rs 2,968 crore in FY26, a compound annual growth rate of 20.6%. Net profit grew from Rs 213 crore in FY22 to Rs 416 crore in FY26, which works out to a compound annual growth rate of 18.2%. The company has a return on equity of 19.8%, a debt to equity ratio of 0.76 and a market capitalisation of Rs 23,316 crore. The stock trades at a P/E of 55.4, above the industry P/E of 37.0. Looking ahead, the company is opening new stores across cities and adding premium and international brands to its range. An omni-channel presence helps it reach a wider set of shoppers.

What risks should investors check before buying pharma, life science and footwear retail stocks?

Ans. Investors should check a few risks before buying pharma, life science and footwear retail stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Client concentration. A few large clients contribute a big share of revenue. Footfall and spending. Store sales follow consumer mood and seasons. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of pharma, life science and footwear retail stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 12 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.